First Wave BioPharma downgraded by Maxim Group
$FWBI
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group downgraded First Wave BioPharma from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2021 | Buy → Hold | Maxim Group |
SC 13G/A - First Wave BioPharma, Inc. (0001604191) (Subject)
SC 13G - First Wave BioPharma, Inc. (0001604191) (Subject)
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today. Entero's common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ticker symbol of ENTO.
First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 732,000 shares of common
Maxim Group downgraded First Wave BioPharma from Buy to Hold
4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
4 - First Wave BioPharma, Inc. (0001604191) (Issuer)
NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. "Terry is an immensely valuable addition to our Board given her experience in business strategy, broad financial transactions and business development, and we are thrilled to welcome her to the team," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Terry has worked with companies large and small and navigated fast-paced, complex business envi
New appointments bring expertise and proven leadership to ZyVersa to support advancement and development of VAR 200 for renal disease, and IC 100 for inflammatory diseasesWESTON, Fla., Jan. 5, 2023 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or ", ZyVersa", ))), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, announced today the appointments of three new independent board members, bringing the total board membership to seven. ZyVersa appoints three
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Sarah Romano has joined the Company as its Chief Financial Officer (CFO) effective immediately. James Sapirstein, Chairman and CEO of First Wave BioPharma, stated, "We are excited to add Sarah to the First Wave BioPharma team. Hiring an individual of her experience and capabilities reflects our commitment to bringing in talented individuals with strong track records. Her recent positions
8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
10-Q - First Wave BioPharma, Inc. (0001604191) (Filer)
8-K - First Wave BioPharma, Inc. (0001604191) (Filer)
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., named President and Chief Operating Officer A strategic U.S. commercial license agreement with a global pharmaceutical company and concurrent institutional investment expected to close in 2H'24 Conference Call Scheduled for Today at 8:30 a.m. ET BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development
BOCA RATON, Fla., Nov. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-system therapies for gastrointestinal diseases, today announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single
BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders in connection with the Company's 2021 Annual Meeting of Stockholders, to be held on December 17, 2021 at 9:00 a.m. EST. The letter provides an update on recent events and an outlook for the Company's clinical programs in 2022. The full text of the letter follows. A MESSAGE FROM OUR CH
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the invest
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that in honor of Celiac Disease Awareness Month in May, it will partner with Celiac Journey, a celiac disease patient advocacy organization, to share an awareness digital display on the Nasdaq Tower in Times Square on Thursday, May 16, at 4:25 p.m. ET. The digital display will also be shown at night as part of the international "Shine a Light on Celiac Disease" initiative to illuminate famous la